For Community Hematologists

Medical Education Built for Community Hematologists

Knowledge Med delivers interactive virtual sessions for community hematologists navigating an increasingly complex treatment landscape — from BTK inhibitor sequencing in CLL to bispecific antibodies in DLBCL to JAK inhibitor selection in myelofibrosis. Every session is led by academic hematologists who specialize in these diseases full-time.

Third-party, non-promotional sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.

Why Knowledge Med

Built for the realities of community hematologists

Specialized heme-onc content

Community hematologists often see the same patient for decades. Knowledge Med sessions go deep on CLL, DLBCL, follicular lymphoma, multiple myeloma, AML, MDS, myelofibrosis, mantle cell lymphoma, and other heme malignancies — the level of depth you need, not a 30,000-foot overview.

Faculty who live in the data

Our hematology faculty are clinical trial leaders at academic centers like Johns Hopkins and Columbia. They know the pivotal data, the subgroup analyses, and the real-world evidence — and they translate it clearly for community practice.

Independent and evidence-based

Third-party, non-promotional content that has been scientifically reviewed. You get objective guidance on treatment sequencing, biomarker interpretation, and toxicity management.

Learn alongside your peers

Live polling shows how community hematologists across the country approach the same clinical decision. You see where the field is converging and where there's genuine uncertainty.

What You Face

Clinical challenges community hematologists navigate

Knowledge Med sessions are built around the real questions that shape daily practice for community hematologists.

  • Navigating BTK inhibitor and BCL-2 inhibitor sequencing in CLL
  • Deciding among CAR-T, bispecifics, and chemoimmunotherapy in lymphoma
  • Managing transplant-ineligible multiple myeloma across multiple lines of therapy
  • Selecting the right JAK inhibitor for myelofibrosis patient profile

Join a Session

Third-party, non-promotional medical education built for community hematologists. Case simulations. Live polling. Personalized insights.

Join a Session